Published in Radiother Oncol on September 08, 2011
Volumetric modulated arc planning for lung stereotactic body radiotherapy using conventional and unflattened photon beams: a dosimetric comparison with 3D technique. Radiat Oncol (2011) 1.05
Dosimetric accuracy and clinical quality of Acuros XB and AAA dose calculation algorithm for stereotactic and conventional lung volumetric modulated arc therapy plans. Radiat Oncol (2013) 0.95
FusionArc optimization: a hybrid volumetric modulated arc therapy (VMAT) and intensity modulated radiation therapy (IMRT) planning strategy. Med Phys (2013) 0.85
Comparison of plan optimization for single and dual volumetric-modulated arc therapy versus intensity-modulated radiation therapy during post-mastectomy regional irradiation. Oncol Lett (2016) 0.84
Comparative planning of flattening-filter-free and flat beam IMRT for hypopharynx cancer as a function of beam and segment number. PLoS One (2014) 0.82
AP-PA field orientation followed by IMRT reduces lung exposure in comparison to conventional 3D conformal and sole IMRT in centrally located lung tumors. Radiat Oncol (2012) 0.78
A novel implementation of mARC treatment for non-dedicated planning systems using converted IMRT plans. Radiat Oncol (2013) 0.77
Optimizing the flattening filter free beam selection in RapidArc®-based stereotactic body radiotherapy for Stage I lung cancer. Br J Radiol (2015) 0.75
Comparison of hybrid volumetric modulated arc therapy (VMAT) technique and double arc VMAT technique in the treatment of prostate cancer. Radiol Oncol (2015) 0.75
An IMRT/VMAT Technique for Nonsmall Cell Lung Cancer. Biomed Res Int (2015) 0.75
Advances in radiotherapy techniques and delivery for non-small cell lung cancer: benefits of intensity-modulated radiation therapy, proton therapy, and stereotactic body radiation therapy. Transl Lung Cancer Res (2017) 0.75
Clinical Application of a Hybrid RapidArc Radiotherapy Technique for Locally Advanced Lung Cancer. Technol Cancer Res Treat (2016) 0.75
Clinical outcomes and patterns of failure after intensity-modulated radiotherapy for nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys (2010) 2.31
Primary tumor volume of nasopharyngeal carcinoma: prognostic significance for local control. Int J Radiat Oncol Biol Phys (2004) 2.05
HER2 overexpression of breast cancers in Hong Kong: prevalence and concordance between immunohistochemistry and in-situ hybridisation assays. Hong Kong Med J (2008) 1.46
Major late toxicities after conformal radiotherapy for nasopharyngeal carcinoma-patient- and treatment-related risk factors. Int J Radiat Oncol Biol Phys (2008) 1.42
Should young age be a contra-indication to breast conservation treatment in Chinese women? Twelve-year experience from a public cancer centre in Hong Kong. Hong Kong Med J (2009) 1.38
Survival outcome of patients with nasopharyngeal carcinoma with first local failure: a study by the Hong Kong Nasopharyngeal Carcinoma Study Group. Head Neck (2005) 1.23
RapidArc radiotherapy planning for prostate cancer: single-arc and double-arc techniques vs. intensity-modulated radiotherapy. Med Dosim (2011) 1.21
A comparison study of different PCR assays in measuring circulating plasma epstein-barr virus DNA levels in patients with nasopharyngeal carcinoma. Clin Cancer Res (2005) 1.14
Outcomes of nasopharyngeal carcinoma screening for high risk family members in Hong Kong. Fam Cancer (2010) 1.10
Familial nasopharyngeal carcinoma in Hong Kong: epidemiology and implication in screening. Fam Cancer (2008) 1.06
N-staging by magnetic resonance imaging for patients with nasopharyngeal carcinoma: pattern of nodal involvement by radiological levels. Radiother Oncol (2006) 1.06
Sensorineural hearing loss after treatment of nasopharyngeal carcinoma: a longitudinal analysis. Int J Radiat Oncol Biol Phys (2008) 1.06
Dose-response relationship of nasopharyngeal carcinoma above conventional tumoricidal level: a study by the Hong Kong nasopharyngeal carcinoma study group (HKNPCSG). Radiother Oncol (2006) 1.04
Recurrent and second primary squamous cell carcinoma of the head and neck: when and how to reirradiate. Head Neck (2014) 1.02
Radical radiotherapy for nasopharyngeal carcinoma in elderly patients: the importance of co-morbidity assessment. Oral Oncol (2011) 0.96
Parapharyngeal extension of nasopharyngeal carcinoma: still a significant factor in era of modern radiotherapy? Int J Radiat Oncol Biol Phys (2008) 0.94
Screening for family members of patients with nasopharyngeal carcinoma. Int J Cancer (2005) 0.94
Epigenetic markers for noninvasive early detection of nasopharyngeal carcinoma by methylation-sensitive high resolution melting. Int J Cancer (2014) 0.90
Potential improvement of tumor control probability by induction chemotherapy for advanced nasopharyngeal carcinoma. Radiother Oncol (2008) 0.90
Cost-analysis of XELOX and FOLFOX4 for treatment of colorectal cancer to assist decision-making on reimbursement. BMC Cancer (2011) 0.89
Neural correlates of an injury-free model of central sensitization induced by opioid withdrawal in humans. J Neurosci (2011) 0.87
Development and validation of the functional assessment of cancer therapy nasopharyngeal cancer subscale. Head Neck (2009) 0.86
Role of STAT3/5 and Bcl-2/xL in 2-methoxyestradiol-induced endoreduplication of nasopharyngeal carcinoma cells. Mol Carcinog (2011) 0.86
Treatment of stage IV(A-B) nasopharyngeal carcinoma by induction-concurrent chemoradiotherapy and accelerated fractionation. Int J Radiat Oncol Biol Phys (2005) 0.83
Treatment of Stage IV(A-B) nasopharyngeal carcinoma by induction-concurrent chemoradiotherapy and accelerated fractionation: impact of chemotherapy schemes. Int J Radiat Oncol Biol Phys (2006) 0.82
Delayed presentation of symptomatic breast cancers in Hong Kong: experience in a public cancer centre. Hong Kong Med J (2010) 0.81
Clinical outcome of breast conservation therapy for breast cancer in Hong Kong: prognostic impact of ipsilateral breast tumor recurrence and 2005 St. Gallen risk categories. Int J Radiat Oncol Biol Phys (2007) 0.81
Can the analysis of ERCC1 expression contribute to individualized therapy in nasopharyngeal carcinoma? Int J Radiat Oncol Biol Phys (2010) 0.81
Adjuvant chemoradiation for resected gastric cancer: a 10-year experience. Gastric Cancer (2011) 0.81
Treatment of primary liver cancer using highly-conformal radiotherapy with kV-image guidance and respiratory control. Radiother Oncol (2011) 0.81
Magnetic Resonance for T-staging of nasopharyngeal carcinoma--the most informative pair of sequences. Jpn J Clin Oncol (2004) 0.80
Severe oral mucositis associated with cancer therapy: impact on oral functional status and quality of life. Support Care Cancer (2009) 0.80
Predictive factors and radiological features of radiation-induced cranial nerve palsy in patients with nasopharyngeal carcinoma following radical radiotherapy. Oral Oncol (2012) 0.79
Chemotherapy for Nasopharyngeal Cancer: Neoadjuvant, Concomitant, and/or Adjuvant. Curr Treat Options Oncol (2015) 0.79
Stereotactic ablative radiotherapy for medically inoperable early stage lung cancer: early outcomes. Hong Kong Med J (2012) 0.78
A patient-reported outcome instrument to assess the impact of oropharyngeal mucositis on health-related quality of life: a longitudinal psychometric evaluation. Support Care Cancer (2008) 0.78
Trends and patterns of breast conservation treatment in Hong Kong: 1994-2007. Int J Radiat Oncol Biol Phys (2008) 0.77
An analysis of the efficacy of serial screening for familial nasopharyngeal carcinoma based on Markov chain models. Fam Cancer (2011) 0.77
Is selective neck irradiation safe for node-negative nasopharyngeal carcinoma? Int J Radiat Oncol Biol Phys (2013) 0.77
Relationships between explanatory style, posttraumatic growth and posttraumatic stress disorder symptoms among Chinese breast cancer patients. Psychol Health (2010) 0.77
Use of Rasch analysis in the evaluation of the Oropharyngeal Mucositis Quality Of Life Scale. Nurs Res (2011) 0.76
New measure of health-related quality of life for patients with oropharyngeal mucositis: development and preliminary psychometric evaluation. Cancer (2007) 0.75
In regards to Chen et al.: Experience in fractionated stereotactic body radiation therapy boost for newly diagnosed nasopharyngeal carcinoma (Int J Radiat Oncol Biol Phys 2006;66:1408-1414). Int J Radiat Oncol Biol Phys (2007) 0.75
Metronomic oral cyclosphosphamide as third-line systemic treatment or beyond in patients with inoperable locoregionally advanced recurrent or metastatic nasopharyngeal carcinoma. Medicine (Baltimore) (2017) 0.75